E
| HTA ID | Drug | Brand | Indication | Assessment status | Date | |
| - | Evolocumab | Repatha® | For both primary hypercholesterolaemia and mixed dyslipidaemia and heterozygous familial hypercholesterolaemia. | Assessment process complete | 16th May 2018 |  |
| - | Exenatide | Bydureon® | For the treatment of type II diabetes mellitus combined with Metformin, Sulphonylurea, Thiazolidinedione, Metform and SU and Metformn and TZD in adults who have not acheived glycaemic control on maximally tolerated doses of these oral therapies. | Rapid review complete | 9th June 2011 | |
